SLC5A2 and coronary artery disorder: Management of patients with coronary artery disease and other risk factors, such as diabetes, with novel therapies like sodium-glucose cotransporter 2 inhibitors may reduce the downstream risk of HF.48,49,50,51 In addition, more effective and evidence-based management of AF with rhythm control strategies, such as catheter ablation, may also contribute to lower HF risk.